Q-omics provides the consensus-scored CXorf21 profile across patient tissues and cancer cell-line models. CXorf21 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, CXorf21 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CXorf21 RNA expression shows 22,357 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, KIRC, and LSCC as cancer lineages where CXorf21 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXorf21 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXorf21 survival associations across molecular data types. CXorf21 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXorf21 RNA expression–survival associations across cancer types. High CXorf21 expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, LUAD, CESC and UCS. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for CXorf21 RNA expression.
This table summarizes CXorf21 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CXorf21. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXorf21 shows lower tumor expression in COAD, LUSC and LUAD and higher tumor expression in KIRC, THCA and HNSC. The KIRC box plot shows higher CXorf21 RNA expression in tumor versus normal tissue (log2 FC = +1.726, t-test p < 0.001).
This table shows molecular features associated with CXorf21 in patient tissues and cancer cell lines. In patient samples, CXorf21 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CXorf21 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
